Efficacy of PreOperative Bevacizumab for Diabetic Eye Disease
Status:
Completed
Trial end date:
2008-06-01
Target enrollment:
Participant gender:
Summary
Reports of the use of intravitreal bevacizumab (Avastin, Genentech) for the reduction of
neovascularization in proliferative diabetic retinopathy have demonstrated significant
regression in the number of new vessels. Reducing the vascularity of neovascular
fibrovascular tissue can potentially reduce bleeding intraoperatively and thus facilitate the
vitrectomy procedure. The investigators chose to investigate the potential benefit of the use
of preoperative bevacizumab in the management of these most complex cases.